Stonebridge Capital Advisors’s CONMED CNMD Stock Holding History

Stonebridge Capital Advisors’s Portfolio CNMD Stock Details CNMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-3	Closed	–	–	996
2022 Q3	$0	Buy	+3	New	+$283	﹤0.01%	1011

Other funds holding CNMD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Stonebridge Capital Advisors's CNMD Position: Q4 2022 in Review

Stonebridge Capital Advisors sold out of CONMED (CNMD) in Q4 2022, closing a stake of 3 shares.

Stonebridge Capital Advisors first reported a position in CNMD in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 239 funds tracked by Wall St. Rank hold CNMD as of Q4 2022.

Stonebridge Capital Advisors reported no remaining CONMED position as of Q4 2022 after selling out during the quarter.
Stonebridge Capital Advisors sold 3 CONMED shares in Q4 2022.
Stonebridge Capital Advisors first reported a position in CONMED in Q3 2022 and held it in 1 quarter.
Stonebridge Capital Advisors's CONMED position peaked at $0 in Q3 2022.
239 funds tracked by Wall St. Rank held CONMED as of Q4 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.